在百万退伍军人计划中,皮肤冠状动脉干预后的CYP2C19多态和临床结果
Catherine Chanfreau-Coffinier1, Kevin A Friede2, Mary E Plomondon3
1VA Salt Lake City Heath Care System, Salt Lake City, Utah, USA.
Clinical pharmacology and therapeutics
|June 3, 2025
概括
在PCI后接受克洛皮多格雷尔治疗的年轻急性冠状动脉综合征患者中,CYP2C19功能丧失等位基因可能会增加主要不良心脏事件的风险. 临床因素对老年患者具有稳定的缺血性心脏病更为关键.
科学领域:
- 心血管医学 心血管医学
- 药物基因组学 药物基因组学
- 干预心脏病学 干预心脏病学
背景情况:
- 已知CYP2C19功能丧失 (LOF) 基因组降低了皮格雷尔在急性冠状动脉综合征 (ACS) 患者的抗血小板疗效,这些患者经过皮肤冠状动脉干预 (PCI).
- 在现实环境中接受PCI的稳定缺血性心脏病 (SIHD) 患者中,CYP2C19基因型对结果的影响仍然不太清楚.
研究的目的:
- 调查CYP2C19 LOF等位基因与主要心脏不良事件 (MACE) 在经过PCI的大量退伍军人队列中的关联.
- 为了比较CYP2C19基因型对ACS患者的MACE风险的影响与SIHD.
主要方法:
- 在2009年至2017年期间,VA百万退伍军人计划中的9061名退伍军人接受了PCI后用克洛皮多格雷尔治疗的回顾性分析.
- 重大心脏不良事件 (MACE) 被定义为心血管死亡,中风或心肌梗塞在PCI后12个月内发生.
- 对CYP2C19 LOF等位基因进行了基因型定型,并根据ACS/SIHD状态和基因型分析了结果,并计算了调整后的危险比率 (aHR).
主要成果:
- 总体而言,28%的患者携带CYP2C19 LOF等位基因. 在LOF载体中观察到MACE风险增加的趋势 (aHR 1.13).
- 这种风险在ACS患者中更为明显 (aHR 1.20),特别是年轻人 (<66岁) (aHR 1.41,P=0.028).
- 在SIHD患者 (aHR1.09) 或较老的ACS患者中,CYP2C19基因型对MACE风险没有显著影响.
结论:
- 在PCI后用克洛皮多格雷尔治疗的年轻ACS患者中,CYP2C19 LOF等位基因可能会增加MACE风险.
- 临床因素似乎比CYP2C19基因型更重要,以确定老年退伍军人患有ACS或任何接受PCI的SIHD患者的MACE风险.
- 这些发现强调了遗传学,临床表现和抗血小板治疗结果之间的复杂相互作用.
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
39
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
39
01:30Acute Coronary Syndrome III: Diagnostic Studies
26
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
26
01:26Coronary Artery Disease IV: Preventive Measures
40
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
40
01:29Cardiomyopathy V: Interprofessional Care
41
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
41
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
54
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
54
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260